ivWatch LLC, which offers continuous monitoring devices for the early detection of peripheral IV infiltrations, has been awarded an Innovative Technology contract from Vizient Inc.
The device can help in early detection of peripheral IV infiltration and extravasation events
The Innovative Technology contracts are reserved for technologies that demonstrate an ability to enhance clinical care or patient safety, Vizient said.
The ivWatch Model 400 continuously monitors a patient’s peripheral IV for evidence of infiltrations, which occur when medication or fluid leaks into the surrounding tissue.
More than 20% of IVs can fail because of infiltration, which can both damage the patient’s tissue and cause a drug delivery error.
“IV infiltration is a major problem that can lead to serious medical complications and even amputation. This contract with Vizient is one more step towards our vision of eliminating the harm associated with IV infiltrations,” said Gary Warren, president and CEO of ivWatch LLC.
Vizient Inc. represents organizations formerly known as VHA Inc., University HealthSystem Consortium, Novation and MedAssets’ Spend and Clinical Resource Management.
